IRCCS Humanitas Research Hospital & Humanitas University
Published November 14, 2022 | Version v1
Dataset Restricted

Dataset related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"

Authors/Creators

  • 1. Division of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy and Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy
  • 2. Division of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy
  • 3. Laboratory of Medical Microbiology and Virology, University Vita-Salute San Raffaele, 20132 Milan, Italy and IRCCS San Raffaele Hospital, 20132 Milan, Italy
  • 4. IRCCS San Raffaele Hospital, 20132 Milan, Italy
  • 5. Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy and IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy
  • 6. IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy
  • 7. Division of Internal Medicine and Liver Disease, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy.
  • 8. Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy
  • 9. Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy and Medical Direction, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy
  • 10. Diagnostic Laboratory, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy
  • 11. Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy and Division of Internal Medicine and Liver Disease, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy

Description

This record contains data related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"

The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (p < 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of >1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80-98, p < 0.0001). Moreover, in the seroconverted patients, a daily dose of >1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of >1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

This set of data is accessible only upon request because it includes sensitive data.

Please write your request to biblioteca@humanitas.it

You are currently not logged in. Do you have an account? Log in here

Additional details

Related works

Is supplement to
Journal article: 10.3390/vaccines10050801 (DOI)
Journal article: 35632557 (PMID)